FDA
-
-
-
-
-
-
-
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
-
-
-
-
-
-
-
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
-
-
-
-
-
-
-
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
-
-
-
-
-
-
-
ARS Pharmaceuticals wins European patent challenge for neffy spray
-
-
-
-
-
-
-
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)
-
-
-
-
-
-
-
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)
-
330,011 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

